Cystic Fibrosis: The Year in Review
Phase 3 testing in 2018
The results indicate that individuals using this therapy had relief from symptoms associated with cystic fibrosis that negatively impact the lungs. The therapy is expected to move on to Phase 3 testing in early 2018. Given the trajectory so far, there are high hopes that this treatment will emerge as a viable new option for patients.
